Strengthening Europe’s antibiotic independence: Sandoz adopts Alpbach Communiqué to safeguard EU-based antibiotic production

Basel / Alpbach, September 15, 2025 - Sandoz (SIX: SDZ / OTCQX: SDZNY), the global leader in generic and biosimilar medicines, recently announced the adoption of a communiqué at the European Forum Alpbach, aimed at safeguarding and strengthening EU-based antibiotic production.

The Alpbach Communiqué supports forthcoming EU legislation aimed at creating favorable conditions for antibiotic Active Pharmaceutical Ingredients (API) manufactured within Europe. This initiative is an important step toward ensuring health security - across Europe and beyond - particularly in antibiotic production.

Antibiotics are essential to modern medicine, yet Europe's production capacity is under threat, with over 80% of global API supply currently sourced from China. This dependency poses serious risks to public health, supply chain resilience, competitiveness, and geopolitical stability.

The Alpbach Communiqué aims to reverse this trend by restoring and safeguarding European sovereignty in antibiotic manufacturing and reinforcing the region's strategic autonomy, while ensuring supply security both within Europe and beyond through measures including additional region-specific partnerships.

The Alpbach Communiqué has been passed to the EU Member States and the European Union's Health Emergency Preparedness and Response Authority's (HERA) for further pursual.

Please find more information about the Alpbach Communiqué here: Link